



**Monique Champagne Appointed President and Chief Executive Officer of
ILKOS THERAPEUTIC**

Laval (Québec), March 2, 2017 - Mark Beaudet, Chairman of ILKOS THERAPEUTIC, is pleased to announce the appointment of Monique Champagne as President and Chief Executive Officer of the Laval biotech firm.

Monique Champagne brings to the company 29 years of experience in clinical research, drug development and regulatory affairs, acquired in the pharmaceutical, biotechnology and contract industries. A creative manager, she has extensive practical experience and expertise in the first phases of oncology drug development, in clinical development in various therapeutic areas, clinic operations management, regulatory affairs, integration and improvement of operational processes, as well as in managing international projects and professional relations with business partners.

Prior to joining ILKOS, Ms. Champagne was Vice-President, Clinical Research and Regulatory Affairs, at Telesta Therapeutics. Before that, she held management positions at, among others, Xanthus Life Sciences, Supratek Pharma, PricewaterhouseCoopers and Wyeth-Ayerst (Pfizer).

Monique Champagne holds a Bachelor of Pharmacy (B.Pharm.), a master's degree in pharmaceutical sciences (M.Sc.) and a pharmacist license in Québec.

ILKOS THERAPEUTIC is a Québec biotech firm tasked with the development of S42909, a compound indicated in the treatment of venous lower limb ulcers. The Laval-based start-up is the result of a \$21 million investment by the Fonds de solidarité FTQ, the CTI Life Sciences Fund and Servier Canada.

Picture of Monique Champagne: <https://fstq.sharefile.com/d-s29d06baa6da4ba2a>

- 30 -

Information for media representatives only:

Micheline Beauvais, CGA, CPA, MBA
CFO / Ilkos Therapeutic Inc.
mbeauvais@ilkostherapeutic.com